The vaccine is intended to address various strains of Covid-19
GSK’s share price rose 0.75% when it opened Monday on news that the company would develop a vaccine.
German pharmaceutical companies GSK and Curevac are working together to develop the next generation of mRNA Covid-19 vaccines.
The company is targeting availability in 2022 and subject to regulatory approval, and development will begin soon.
The 150 million euro collaboration could lead to a vaccine with a multivalint approach that can target multiple emerging variants.
New variations of Covid-19 have been appearing in Brazil, South Africa and the UK as the world continues to fight against infectious diseases.
GSK CEO Emma Walmsley believes the vaccine developed by the research project could play a leading role in the fight against the coronavirus pandemic.
“We believe that the next generation of vaccines is extremely important in the ongoing battle with Covid-19. This new collaboration is based on existing relationships with Curevac, and together This means combining mRNA with scientific expertise in vaccine development to accelerate and accelerate the development of new Covid-19 vaccine candidates,” Walmsley said.
GSK will also support Curevac’s efforts to manufacture up to 100 million doses of vaccine candidate CVNCOV in 2021.
Curevac CEO Franz-Werner Haas welcomed GSK’s expertise.
“We are extremely pleased to be able to build on our existing relationship with GSK, along with the new agreement to jointly develop the next-generation mRNA-based vaccine, in addition to our current candidate CVNCOV. With the help of vaccine expertise, we are equipping future health challenges to tackle new vaccines,” says Haas.
GSK bought a 10% stake in Curevac in 2020 to combat the coronavirus and other future outbreaks.
